Anti-estrogen medication reduces risk of dying from lung cancer
Key points
- A new study has found that tamoxifen, an anti-estrogen breast cancer medication, may reduce an individual's risk of death from lung cancer.
- Previous research suggests that menopausal hormone therapy increases women's risk of dying from lung cancer.
- The investigators found that 40 women in the study developed lung cancer.
- "Our results support the hypothesis that there is a hormonal influence on lung cancer which has been suggested by findings such as the presence of estrogen and progesterone receptors in a substantial proportion of lung cancers," said Dr.
A new study has found that tamoxifen, an anti-estrogen breast cancer medication, may reduce an individual's risk of death from lung cancer. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study supports the hypothesis that there is a hormonal influence on lung cancer and that estrogen levels play a role in lung cancer patients' prognosis.
Previous research suggests that menopausal hormone therapy increases women's risk of dying from lung cancer. If this is true, the use of anti-estrogens should have the opposite effect. Elisabetta Rapiti, MD, of the Geneva Cancer Registry led a study that compared lung cancer incidence and mortality among breast cancer patients who were and were not treated with anti-estrogen therapy. The study included all 6,655 women diagnosed with breast cancer between 1980 and 2003 and registered at the Geneva Cancer Registry. Among these women, 46 percent (3,066) received anti-estrogens. All women were followed for occurrence and death from lung cancer until December 2007.
The investigators found that 40 women in the study developed lung cancer. Incidences of lung cancer was not significantly different between breast cancer patients who were and were not treated with anti-estrogens compared with the general population; however, fewer women taking anti-estrogens died from lung cancer than expected. Specifically, there were 87 percent fewer cases of death due to lung cancer in the anti-estrogen group than in the general population.
"Our results support the hypothesis that there is a hormonal influence on lung cancer which has been suggested by findings such as the presence of estrogen and progesterone receptors in a substantial proportion of lung cancers," said Dr. Rapiti. "If prospective studies confirm our results and find that anti-estrogen agents improve lung cancer outcomes, this could have substantial implications for clinical practice," she added.
###
Contact: Jennifer Beal
healthnews@wiley.com
44-124-377-0633
Wiley-Blackwell
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsAnti-gout drug may decrease risk for colorectal adenoma progression
Allopurinol, a relatively inexpensive anti-gout medication that has been on the market for more than 20 years, may have some activity against colorectal adenomas, according to data presented at the Ninth Annual AACR…
10 November 2010
NewsCertain pain medications do not appear to be associated with skin cancer risk
Contrary to previous hypotheses, the use of non-steroidal anti-inflammatory drugs does not appear associated with risk of squamous cell skin cancer, according to a report posted online today that will appear in the…
16 February 2010
NewsBreastfeeding reduces risk of breast cancer in women with a family history of the disease
According to a new study, women with a family history of breast cancer were 59 percent less likely to develop breast cancer themselves if they breastfed their children. "This is good news for women with a family history…
